SG11201702162PA - 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs - Google Patents

7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs

Info

Publication number
SG11201702162PA
SG11201702162PA SG11201702162PA SG11201702162PA SG11201702162PA SG 11201702162P A SG11201702162P A SG 11201702162PA SG 11201702162P A SG11201702162P A SG 11201702162PA SG 11201702162P A SG11201702162P A SG 11201702162PA SG 11201702162P A SG11201702162P A SG 11201702162PA
Authority
SG
Singapore
Prior art keywords
piperazinyl
morpholinyl
anticancer drugs
pyridine derivatives
methyl thieno
Prior art date
Application number
SG11201702162PA
Other languages
English (en)
Inventor
Durga Prasad Konakanchi
Subba Rao Pula
Rama Krishna Pilli
Lakshmana Viswa Venkata Pavan Kumar Maddula
Srinivasa Krishna Murthy Konduri
Janaki Rama Rao Ravi
Naga Vasanta Srinivasu Vuppalapati
Sandeep Kumar Thoota
Pulla Reddy Muddasani
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of SG11201702162PA publication Critical patent/SG11201702162PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201702162PA 2014-12-11 2014-12-11 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs SG11201702162PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2014/000770 WO2016092556A1 (en) 2014-12-11 2014-12-11 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs

Publications (1)

Publication Number Publication Date
SG11201702162PA true SG11201702162PA (en) 2017-04-27

Family

ID=52595387

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702162PA SG11201702162PA (en) 2014-12-11 2014-12-11 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs

Country Status (31)

Country Link
US (1) US10106554B2 (zh)
EP (1) EP3230289B1 (zh)
JP (1) JP6454419B2 (zh)
KR (1) KR102328921B1 (zh)
CN (1) CN107074873B (zh)
AP (1) AP2017009749A0 (zh)
AU (1) AU2014413483B2 (zh)
BR (1) BR112017005518B1 (zh)
CA (1) CA2959980C (zh)
CO (1) CO2017002266A2 (zh)
CY (1) CY1122080T1 (zh)
DK (1) DK3230289T3 (zh)
EA (1) EA036819B1 (zh)
ES (1) ES2750268T3 (zh)
HR (1) HRP20192041T1 (zh)
HU (1) HUE047144T2 (zh)
IL (1) IL252254B (zh)
LT (1) LT3230289T (zh)
MA (1) MA40110B2 (zh)
MX (1) MX2017004782A (zh)
MY (1) MY188946A (zh)
NZ (1) NZ729078A (zh)
PH (1) PH12017500342A1 (zh)
PL (1) PL3230289T3 (zh)
PT (1) PT3230289T (zh)
RS (1) RS59409B1 (zh)
SG (1) SG11201702162PA (zh)
SI (1) SI3230289T1 (zh)
UA (1) UA117318C2 (zh)
WO (1) WO2016092556A1 (zh)
ZA (1) ZA201701036B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022006977A2 (pt) * 2019-10-11 2022-09-20 Incyte Corp Aminas bicíclicas como inibidores de cdk2
CA3165267A1 (en) 2019-12-20 2021-06-24 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof
IL307871A (en) * 2021-04-21 2023-12-01 Natco Pharma Ltd PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579526A (en) 1968-11-13 1971-05-18 Research Corp Preparation of thienopyridines
FR2411838A1 (fr) 1977-12-19 1979-07-13 Parcor Nouveaux derives des thieno (2-3-c) et (3,2-c) pyridines, leurs procede de preparation et leur application therapeutique
US4839365A (en) 1987-05-19 1989-06-13 Shinogi & Co., Ltd. Thienopyridine derivatives useful in treating gastric ulcers
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
MXPA06013250A (es) 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
GB0608264D0 (en) * 2006-04-26 2006-06-07 Piramed Ltd Pharmaceutical compounds
KR20090021155A (ko) * 2006-04-26 2009-02-27 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제제로서의 피리미딘 유도체
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
GB0723748D0 (en) 2007-12-04 2008-01-16 Ucb Pharma Sa Therapeutic agents
CA2719032C (en) 2008-03-31 2016-11-08 Steven Do Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
DK2385832T3 (en) * 2009-01-08 2015-09-21 Curis Inc Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel
CA2775942A1 (en) 2009-09-29 2011-04-07 Xcovery Holding Company Llc Pi3k (delta) selective inhibitors
US9073927B2 (en) * 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
MX2013008822A (es) * 2011-02-09 2013-10-07 Hoffmann La Roche Compuestos heterociclicos como inhibidores de cinasa fosfatidilinositol-3 (pi3).

Also Published As

Publication number Publication date
EA036819B1 (ru) 2020-12-23
PL3230289T3 (pl) 2020-03-31
JP2017537139A (ja) 2017-12-14
IL252254A0 (en) 2017-07-31
CN107074873A (zh) 2017-08-18
BR112017005518B1 (pt) 2022-11-29
IL252254B (en) 2019-08-29
MA40110B2 (fr) 2020-12-31
ES2750268T3 (es) 2020-03-25
EP3230289B1 (en) 2019-08-14
WO2016092556A1 (en) 2016-06-16
LT3230289T (lt) 2019-10-10
SI3230289T1 (sl) 2019-10-30
ZA201701036B (en) 2019-06-26
EP3230289A1 (en) 2017-10-18
HRP20192041T1 (hr) 2020-02-07
DK3230289T3 (da) 2019-10-28
US20170320891A1 (en) 2017-11-09
US10106554B2 (en) 2018-10-23
NZ729078A (en) 2021-07-30
PH12017500342A1 (en) 2017-07-17
AU2014413483B2 (en) 2019-07-25
PT3230289T (pt) 2019-10-30
KR102328921B1 (ko) 2021-11-19
AP2017009749A0 (en) 2017-02-28
CA2959980A1 (en) 2016-06-16
CN107074873B (zh) 2022-01-07
CA2959980C (en) 2023-04-25
HUE047144T2 (hu) 2020-04-28
CY1122080T1 (el) 2020-11-25
EA201791294A1 (ru) 2017-11-30
RS59409B1 (sr) 2019-11-29
MA40110A1 (fr) 2017-12-29
AU2014413483A1 (en) 2017-03-09
BR112017005518A2 (pt) 2017-12-05
KR20170090434A (ko) 2017-08-07
UA117318C2 (uk) 2018-07-10
MY188946A (en) 2022-01-14
CO2017002266A2 (es) 2017-05-31
MX2017004782A (es) 2017-07-27
JP6454419B2 (ja) 2019-01-16

Similar Documents

Publication Publication Date Title
HK1244804A1 (zh) 4h-吡咯並[3，2-c]吡啶-4-酮衍生物
IL252065B (en) Thiano[2,3-c]pyrrol-4-ion derivatives as erk inhibitors
IL251441A0 (en) History of imidazo pyridine and pharmaceutical preparations containing them
HK1231416A1 (zh) 西羅莫司及其衍生物的絡合物、其製備方法以及含有其的藥物組合物
IL251780B (en) Derivatives of 5-(3-hydroxy-propyn-1-yl)-3-(2-amino-pyrimidinyl)-h1-pyrrolo[c-3,2] pyridine and pharmaceutical preparations containing them
IL252254A0 (en) Anticancer drugs derived from 7-morpholinyl-2-n-piperazinyl-methyl thiano-[3,2-c]-pyridine
IL251067B (en) 4-(phenyl/heteroaryl)-7-(phenyl/pyrid-4-yl)-8,5-dihydro-8,5-ethanopyrido[4,3-d]pyrimidine derivatives and pharmaceutical preparations containing them
EP3102036A4 (en) 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof
IL250267B (en) History of indolizine, their preparation and pharmaceutical preparations containing them
IL252578B (en) History of 1h- pyrazolo (3.4-c) [5.1] naphthyridine 4-(5h)-one and pharmaceutical preparations containing them
EP3190111A4 (en) Pyrazolo[3,4-c]pyridine derivatives
IL252579B (en) History of methyl-(1h-pyrazolo-4-yl-)-3-methyl-1h-pyrazolo[3,4-d]pyrimidine and pharmaceutical preparations containing them
EP3302060A4 (en) Pyrazolo[4,3-c]quinoline derivatives for inhibition of -glucuronidase
GB201522532D0 (en) Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
IL243739A0 (en) History of 1h-pyrazolo[4,3-b]pyridine and their pharmaceutical preparations for the treatment of proliferative disorders
EP3150584A4 (en) 3,4-dihydroquinazoline derivative and complex preparation containing same
HUE038944T2 (hu) Tiokromeno[2,3-c]kinolin-12-on származékok és topoizomeráz inhibitorként való alkalmazásuk
GEP20197016B (en) 7-(morpholinyl)-2-(n-piperazinyl)methyl thieno[2,3-c]pyridine derivatives as anticancer drugs
AU2014904868A0 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS